Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jul-Aug;46(4):612-613.
doi: 10.1590/S1677-5538.0343.1.

Editorial Comment: Overall survival prediction in metastatic castration resistant prostate cancer treated with radium-223

Rodolfo Borges Dos Reis  1 , Valdair Muglia  2 , Eliney F Faria  3   4
Affiliations
Editorial

Editorial Comment: Overall survival prediction in metastatic castration resistant prostate cancer treated with radium-223

Rodolfo Borges Dos Reis et al. Int Braz J Urol. 2020 Jul-Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None declared.

Comment on

References

    1. 1. Roodman GD. Mechanisms of bone metastasis. Discov Med. 2004;4:144-8. - PubMed
    2. Roodman GD. Mechanisms of bone metastasis. Discov Med. 2004;4:144–148. - PubMed
    1. 2. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-23. - PubMed
    2. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223. - PubMed
    1. 3. Heidenreich A, Gillessen S, Heinrich D, Keizman D, O’Sullivan JM, Carles J, et al. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and boné metastases treated in an international early access program. BMC Cancer. 2019;19:12. - PMC - PubMed
    2. Heidenreich A, Gillessen S, Heinrich D, Keizman D, O’Sullivan JM, Carles J, et al. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and boné metastases treated in an international early access program. 12BMC Cancer. 2019;19 - PMC - PubMed
    1. 4. Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and boné metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:408-19. - PubMed
    2. Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and boné metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:408–419. - PubMed
    1. 5. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77:508-47. - PubMed
    2. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77:508–547. - PubMed

LinkOut - more resources